Does increasing treatment frequency address sub-optimal responses to ivermectin for the control and elimination of river blindness by Frempong, K F et al.
Clinical Infectious Diseases
M A J O R A R T I C L E
Does Increasing Treatment Frequency Address Suboptimal
Responses to Ivermectin for the Control and Elimination of
River Blindness?
Kwadwo K. Frempong,1,a Martin Walker,2,a Robert A. Cheke,2,3 Edward Jenner Tetevi,4 Ernest Tawiah Gyan,4 Ebenezer O. Owusu,5 Michael D. Wilson,1
Daniel A. Boakye,1 Mark J. Taylor,6 Nana-Kwadwo Biritwum,7 Mike Osei-Atweneboana,4 and María-Gloria Basáñez2
1Noguchi Memorial Institute for Medical Research, University of Ghana, Legon; 2London Centre for Neglected Tropical Disease Research, Department of Infectious Disease Epidemiology, School of
Public Health, Imperial College London, and 3Natural Resources Institute, University of Greenwich at Medway, Chatham Maritime, United Kingdom; 4Council for Scientific and Industrial Research,
Water Research Institute, Accra, and 5Department of Animal Biology and Conservation Science, University of Ghana, Legon; 6Department of Parasitology, Liverpool School of Tropical Medicine, United
Kingdom; and 7Ghana Health Service, Accra
Background. Several African countries have adopted a biannual ivermectin distribution strategy in some foci to control and
eliminate onchocerciasis. In 2010, the Ghana Health Service started biannual distribution to combat transmission hotspots and sub-
optimal responses to treatment. We assessed the epidemiological impact of the first 3 years of this strategy and quantified responses to
ivermectin over 2 consecutive rounds of treatment in 10 sentinel communities.
Methods. We evaluated Onchocerca volvulus community microfilarial intensity and prevalence in persons aged ≥20 years before
the first, second, and fifth (or sixth) biannual treatment rounds using skin snip data from 956 participants. We used longitudinal
regression modeling to estimate rates of microfilarial repopulation of the skin in a cohort of 217 participants who were followed up
over the first 2 rounds of biannual treatment.
Results. Biannual treatment has had a positive impact, with substantial reductions in infection intensity after 4 or 5 rounds in
most communities. We identified 3 communities—all having been previously recognized as responding suboptimally to ivermectin—
with statistically significantly high microfilarial repopulation rates. We did not find any clear association between microfilarial
repopulation rate and the number of years of prior intervention, coverage, or the community level of infection.
Conclusions. The strategy of biannual ivermectin treatment in Ghana has reduced O. volvulus microfilarial intensity and prev-
alence, but suboptimal responses to treatment remain evident in a number of previously and consistently implicated communities.
Whether increasing the frequency of treatment will be sufficient to meet the World Health Organization’s 2020 elimination goals
remains uncertain.
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In 1987, soon after ivermectin became licensed for human use
[1], and following the first community trials [2], Ghana be-
came one of the first countries to introduce mass treatment
to control onchocerciasis (river blindness). Ivermectin kills
Onchocerca volvulus microfilariae (the larval progeny of
adult worms that are transmissible to Simulium blackfly vectors)
and temporarily sterilizes female worms such that numbers of
microfilariae remain suppressed for at least 3 months following
treatment [3]. Subsequently, females regain fertility and microfi-
lariae repopulate the skin. Hence, ivermectin can only control
onchocerciasis-associated disease—caused by immunopatholog-
ical responses to chronic infection of the skin and ocular tissue by
microfilariae [4]—when given at regular intervals. Infection can
be eliminated if microfilariae are suppressed long enough to
ensure that transmission is interrupted for at least 10 years, the
average lifespan of adult worms [5]. Mass treatments with iver-
mectin have successfully eliminated onchocerciasis from foci in
Mali and Senegal [6] (with annual or biannual distribution), Ni-
geria [7], Mexico [8], Colombia [9], Ecuador [10], and northern
Venezuela [11]. (The strategy in Latin America has been mostly
biannual treatment.) National programs in Ethiopia and Uganda,
among others, have adopted biannual distribution in some foci to
accelerate progress toward elimination [12–14].
Despite years of ivermectin treatment in Ghana, and vector
control in its savannah habitats, onchocerciasis still affects thou-
sands of communities within 66 districts [15], and approximately
3.2 million people remain at risk of infection [16]. The resilience
of onchocerciasis is probably partly due to poor responses to iver-
mectin in several Ghanaian communities [17, 18], raising fears
of decreased ivermectin efficacy. In a community of normally
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responding individuals, microfilariae are expected to reach about
10% of their pretreatment numbers 6 months after treatment,
and about 20% one year after treatment [3, 17]. In suboptimally
responding communities, microfilarial repopulation rates 6
months after treatment have been observed at >50% [19]. Some
of these communities are those that have been treated with the
most rounds of ivermectin [20].
In 2010, in response to the persistence of onchocerciasis in
Ghana, the Neglected Tropical Diseases Programme (NTDP)
of the Ghana Health Service (GHS) adopted a biannual treat-
ment strategy in 44 of 77 endemic communities [21]. Here,
we report microfilarial loads and prevalence in 10 NTDP senti-
nel communities—some previously identified as responding
suboptimally to ivermectin—before and after 4 (or 5) rounds
of biannual treatment. We evaluate responses to ivermectin by
estimating rates of microfilarial repopulation in cohorts of indi-
viduals followed up at 3 and 6 months after treatment, compar-
ing skin repopulation rates with community endemicity,
therapeutic coverage, and number of years of prior ivermectin
treatment. We discuss our results in the contexts of historical
epidemiological data collected from these communities during
annual ivermectin distribution and the World Health Organiza-
tion’s (WHO) goals to eliminate onchocerciasis [22].
METHODS
Ethical Approval
Ethical approval was obtained from the ethics review commit-
tees of the Noguchi Memorial Institute for Medical Research,
Ghana (NMIMR-IRB CPN 032110-11), the Ghana Health
Service (GHS ERC 04_3_11), and the Imperial College London
Research and Ethics Committee (ICREC_11_2_4).
Study Site
The study was conducted in 10 onchocerciasis-endemic commu-
nities within savannah regions of Ghana (Figure 1). The commu-
nities were selected from some of the endemic areas where
concerns on ivermectin efficacy have been previously reported
[19]. By the time of this investigation, study communities had re-
ceived between 14 and 23 rounds of annual ivermectin treatment.
Study Design
The 10 selected communities had been scheduled to receive
mass biannual treatments with ivermectin from July 2010. We
used the inclusion/exclusion criteria for selecting communities
described elsewhere [19], including communities previously
identified as responding suboptimally to ivermectin [17, 18,
20]. We recruited adults aged ≥18 years, randomly selected
from different households. The number of eligible participants
Figure 1. Map of Ghana indicating administrative regions and locations of study communities.
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represented about 50%–70% of the total population within the
10 studied communities. Those who were included represented
about 10%–40% of the total population and, of the total eligible
population, approximately 70% in small communities (such as
Asubende, with a population of 87) and roughly 20% in larger
communities (such as New Longoro andWiae with populations
of 1650 and 1611, respectively). The objectives and schedules of
the study were explained to every individual, and those who
agreed to participate signed a consent form.
Figure 2 illustrates the study design and times of treatment
with ivermectin (150 µg/kg, directly observed) using an exam-
ple timeline of 6 trial participants. Skin snips of 956 consenting
participants were taken in July 2010 just before the first round of
biannual ivermectin treatment. All 956 participants were skin
snipped 6 months later, in January 2011, just before the second
biannual treatment round. A total of 217 (22.7%) of these par-
ticipants (Table 1), who were positive for microfilariae in July
2010 (eg, participants 1–5 in Figure 2), formed a cohort for eval-
uating rates of skin microfilarial repopulation. Within this co-
hort, the 186 participants (Table 1) positive for microfilariae
in January 2011 (eg, participants 1–4 in Figure 2) were skin
snipped in April 2011 and in July 2011, just before the third
round of biannual ivermectin treatment (some participants
were lost to follow-up, eg, participants 3 and 4 in Figure 2).
Three additional rounds of ivermectin treatment were distribu-
ted approximately every 6 months, in April 2012, December
2012, and June 2013, as part of GHS NTDP activities. Before
the final round of treatment, in June 2013, a final round of
Figure 2. Schematic timeline and illustrative history of 6 trial participants of the study used to evaluate community trends in infection and rates of microfilarial repopulation
following the onset of a biannual treatment strategy in 10 Ghanaian communities. Participants 1–6 represent 6 of the 956 consenting individuals from whom skin snips were
taken in July 2010, just before the first round of biannual ivermectin treatment, and 6 months later in January 2011, just before the second round of biannual ivermectin
treatment. Participants 1–5 were positive for microfilariae in July 2010 and hence were included in the cohort of 217 individuals for evaluating rates of skin microfilarial
repopulation. Participants 1–4 represent 4 of the 186 individuals who were microfilaria positive in January 2011, with participants 1 and 2 successfully followed up and
skin snipped in April 2011 and again in July 2011, just before the third round of biannual ivermectin treatment. Participants 1, 3, 4, and 6 represent 4 of the original 956
participants who agreed to be skin snipped for a final time in June 2013, just before the final round of treatments delivered by the Ghana Health Service Neglected Tropical
Diseases Programme. The months given on the timeline are the modal months of treatment activity among the 10 communities, but there is significant variation in the months
and exact dates, especially for the biannual treatments given after July 2011 (see Figure 3 for exact dates).
Table 1. Longitudinal Cohorts of Participants in 10 Ghanaian
Communities Who Were Followed up and Skin Snipped Over the First 2
Rounds of Biannual Treatment With Ivermectin
Community
Month and Year (Months Since Preceding
Round of Treatment)
July 2010
(0)a
January 2011
(6)b
April 2011
(3)
July 2011
(6)
Agborlekame 1 63 27 23 20
Asubende 34 9 8 9
Baaya 129 1 1 1
Jagbenbendo 107 50 47 46
Kyingakrom 82 14 12 12
New Longoro 126 17 13 15
Ohiampe 85 5 5 4
Senyase 64 8 6 7
Takumdo 108 50 48 44
Wiae 158 26 23 24
Total 956 217 186 182
a Only participants positive for microfilariae were followed up in January 2011.
b Only participants positive for microfilariae were followed up in April 2011 and July 2011.
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skin snipping of consenting participants (eg, participants 1, 3, 4,
and 6 in Figure 2) was repeated. Techniques used to count mi-
crofilariae in skin snip biopsies are described in the Supplemen-
tary Methods.
Community Microfilarial Load and Community Microfilarial Prevalence
We calculated community microfilarial load (CMFL) [23] and
community microfilarial prevalence (CMFP) as our primary
and secondary indicators of community infection levels in the
adult (aged ≥20 years) population. These were calculated before
the first round of biannual treatment in July 2010, before the
second round in January 2011, and before the fifth or sixth
round in March 2013 or June 2013 (the schedules of each com-
munity differed slightly). CMFL and CMFP calculations are
given in the Supplementary Methods.
Community Treatment History and Coverage
We obtained data on community treatment coverage (Supple-
mentary Figure A) at all treatment rounds from the NTDP to fa-
cilitate interpretation of CMFL and CMFP throughout the study.
Coverage was calculated using treatment and census data provid-
ed by the community ivermectin distributors to the NTDP. It re-
fers to the therapeutic coverage in the total population. Historical
records of coverage were also obtained from the GHS NTDP.
Microfilarial Repopulation
We constructed log-linear marginal regression models [24] to
describe the average number of microfilariae per skin snip
(mf/ss) in the longitudinal cohort of 217 individuals (Table 1;
Figure 2), adjusting for community, participant age, and sex.
We constructed 2 models to analyze the data (Table 2). Both
permit repopulation rates to vary among communities, but
the first (Model 1A and 1B, Table 2) permits repopulation
rates to vary between the 2 consecutive repopulation periods,
whereas the second (Model 2, Table 2) estimates a single com-
munity-specific repopulation rate, combining information from
both repopulation periods. Mathematical details are given in the
Supplementary Methods.
We compared microfilarial repopulation rates graphically
and by identifying communities with statistically significantly
different estimates compared with a reference community (Ta-
kumdo). We also explored graphically how repopulation rates
correlated with prior number of years of ivermectin treatment,
therapeutic coverage, and CMFL just before the start of biannu-
al treatment.
RESULTS
Trends in Community Infection
Figure 3 presents community-specific CMFLs calculated in July
2010, January 2011, and March (or June) 2013 (CMFPs are pre-
sented in Supplementary Figure B). We include the dates when
each round of biannual treatment was distributed and the pop-
ulation coverage. The impact of the first round of biannual
treatment appears somewhat greater than that in subsequent
rounds, as demonstrated by the slightly faster decline in
CMFL between round 1 (July 2010), and round 2 (January
2011), compared with that between round 2 and the final assess-
ment of infection levels in March (or June) 2013 (compare the
gradients of the dotted lines in Figure 3). This trend is most ap-
parent in Asubende, Jagbenbendo, New Longoro, Senyase, and
Wiae, and least pronounced in Agborlekame 1 and Takumdo.
In Ohiampe, community infection levels were greater in June
2013 than in July 2010, despite 4 rounds of treatment (1
round was missed in the first quarter of 2013).
Trends in Microfilarial Repopulation
Figure 4 presents the observed and model-fitted (Model 1A,
Table 2) mean number of mf/ss by sampling date and commu-
nity in the reference demographic stratum of males in the age
group 21–40 years. We also include the model-predicted
mean number of mf/ss in October 2010 (3 months after the
first round of biannual treatment), indicating the likely micro-
filarial dynamics during the first 6-month repopulation period.
In general, mean numbers of mf/ss per stratum are lower after
the second repopulation period than after the first; microfilariae
cannot repopulate completely in 6 months before further sup-
pression by another treatment round. Mean numbers of mf/ss
per stratum in January 2011, 6 months after the start of biannu-
al treatment, are quite high compared with those in July 2010
Table 2. Key Features of the Log-Linear Marginal Regression Models Used to Describe the Observed Microfilarial Counts in the Longitudinal Cohort
Type Variant Key Features
Model 1 A and B • Response/outcome variable defined by individual microfilarial counts
• Modeled mean number of microfilariae per participant adjusted for the covariates age group (18–20, 21–40, 41–60, and 61–80), sex, and
community
• Microfilarial repopulation rates permitted to vary among communities and between repopulation periods by including sampling time as a
categorical covariate interacting with community
B • Microfilarial repopulation rates adjusted by exact number of days since preceding round of ivermectin treatment yielding standardized
repopulation rates (eg, 6-month repopulation rates)
Model 2 . . . • Response/outcome variable defined by individual microfilarial counts
• Modeled mean number of microfilariae per participant adjusted for the covariates age group (18–20, 21–40, 41–60, and 61–80), sex, and
community
• A single microfilarial repopulation rate estimated for each community, combining information from both repopulation periods, by including
sampling time as a continuous covariate—defined as days since preceding ivermectin treatment—interacting with community
• Additive, community-wide adjustments for potentially different repopulation rates between 2 repopulation periods
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(one expects microfilariae to reach about 10% of their pretreat-
ment population level after 6 months [3]).
Microfilarial Repopulation Rates
We define the rate of microfilarial repopulation as the mean
number of mf/ss expressed as a percentage of the mean imme-
diately before the preceding treatment with ivermectin. This
captures how quickly microfilariae reappear in the skin between
consecutive treatment rounds. Figure 5 provides standardized
6-month repopulation rates, adjusted by the differing exact
durations between sampling times (calculated from Model 1B
in Table 2; nonstandardized repopulation rates are depicted in
Supplementary Figure C). These estimates confirm that micro-
filarial repopulation rates are generally quite high—typically ap-
proximately 50% during the first period of repopulation—and
similar, albeit somewhat more variable, after the second repop-
ulation period. The repopulation rates in Asubende and Kyin-
gakrom after the second round of treatment are statistically
significantly higher than in the reference community of
Takumdo.
Figure 6 presents the single relative rates of repopulation by
community (estimated using Model 2, Table 2) compared to
Takumdo. Over both repopulation periods, rates of repopula-
tion are statistically significantly (P < .05) higher in Asubende,
Kyingarom, and New Longoro compared with Takumdo.
Graphically, we find no obvious association between the relative
rate of microfilarial repopulation and (1) the number of annual
treatments with ivermectin before the start of the study
(Figure 6B), (2) the CMFL before the first biannual treatment
(Figure 6C), or (3) the average coverage of ivermectin
Figure 3. Trends in community microfilarial loads (CMFLs) in 10 Ghanaian communities from the onset of a biannual ivermectin treatment strategy. CMFL is defined as the
geometric mean number of microfilariae per skin snip in people aged ≥20 years. Colored arrows indicate dates when mass treatment with ivermectin was distributed, by either
the authors or the community ivermectin distributors. Ivermectin was administered directly after skin snipping on dates when microfilarial load was assessed. Data on the
community therapeutic coverage of ivermectin were collated by the Ghana Health Service. The 6 scheduled rounds of biannual ivermectin treatment were successfully delivered
to only 5 (Asubende, Baaya, Kyingakrom, New Longoro, and Senyase) of the 10 communities; the other communities (Agborlekame 1, Jagbenbendo, Ohiampe, Takumdo, and
Wiae) achieved 5 rounds of biannual treatment. Vertical lines indicate 95% confidence intervals calculated using a nonparametric bootstrap technique (Supplementary Meth-
ods). Dotted lines join estimated values and are for presentation purposes only. Triangles indicate times of ivermectin treatment, and numbers above triangles indicate the
therapeutic coverage in the whole community.
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distribution during the cohort component of the study (Fig-
ure 6D; see Supplementary Figure A for disaggregated coverage
data).
DISCUSSION
Onchocerciasis in Ghana remains resilient to the long-standing
and large-scale (antivectorial and antiparasitic) interventions im-
plemented over the past 40 years [25]. Despite having been ear-
marked for elimination as a public health problem by 2015 [16],
there exist persistent hotspots of transmission [19, 26, 27] and re-
ports ofO. volvulusmicrofilariae repopulating the skin of patients
faster than expected following treatment with ivermectin [19, 20],
a phenomenon also documented in Cameroon [28]. In 2010, and
responding to this challenge, the GHS implemented biannual
mass ivermectin treatment in many endemic communities
[21]. We report on trends in community-wide infection with
O. volvulus in 10 Ghanaian communities over the first 3 years
of this biannual strategy and evaluate rates of microfilarial repop-
ulation in cohorts of participants over the first 2 rounds of
treatment.
The last systematic evaluation of community infection levels in
many of the studied communities was in 2004–2005, after 10–18
annual mass ivermectin treatments [19] (Supplementary Tables
A and B). Comparing these values with infection levels in July
2010 shows that the intervening 6 years of annual ivermectin
mass treatment have reduced CMFLs generally by at least 50%.
Figure 4. Trends in mean numbers of microfilariae per participant in 10 Ghanaian communities from the onset of a biannual ivermectin treatment strategy. Data points
represent observed mean microfilarial loads, by community, in the reference strata of males within the age group 21–40 years. The solid vertical lines are corresponding 95%
bootstrap confidence intervals. Triangles indicate when ivermectin was administered to the study participants. Solid lines join fitted estimated values—and in the case of
October 2010, predicted values—from the marginal regression model that includes additive stratum adjustments for age group and sex, and interactive adjustments between
sampling date and community (Model 1A in Table 2). Dotted lines join the corresponding 95% confidence bounds calculated using robust sandwich estimators of coefficient
standard errors (Supplementary Methods). The predicted values in October 2010 are provided to assist the reader to envisage the likely dynamics in mean numbers of micro-
filariae per skin snip between the first and second sampling dates. These predictions were generated from the marginal regression model that treats the time since the
preceding ivermectin treatment as a continuous variable (Model 2 in Table 2) and assumes that (hypothetical) microfilarial sampling took place midway between the July
2010 and January 2011 sampling times. Data from Baaya are not shown because only 1 participant was microfilaria positive and followed up in this community (Table 1),
leading to very large associated estimates of uncertainty.
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Infection levels were further reduced by March or June 2013,
after 3 years of biannual treatment. Reductions in CMFL were
>36% in most communities and the CMFP was statistically sig-
nificantly <10% in 5 of 10 communities (Supplementary Tables
A and B). Hence, the biannual strategy has had a positive impact.
Whether residual infection levels constitute a public health
problem would be best evaluated by measuring levels of on-
chocerciasis-associated morbidity. However, it is hard to envisage
declaring the problem eliminated in communities where micro-
filarial prevalence is >10%, or >20% as in Jagbenbendo. More-
over, whether biannual treatments will ultimately be sufficient
to eliminate infection will depend on local transmission and pro-
grammatic conditions, particularly on the intensity of blackfly
biting [25, 26] and the sustainability of high levels of treatment
coverage and adherence [29, 30]. One of the objectives of the
Neglected Tropical Diseases Modelling Consortium (www.
ntdmodelling.org) is to determine what intervention strategies
will be necessary to eliminate infection in the timelines set out
by the WHO Roadmap on Neglected Tropical Diseases [22].
The 6-month rates of repopulation estimated here are broadly
around 50% and are high compared with the expected 10% from
parasite populations predominantly naive to ivermectin [3].They
are also higher than those estimated from some of the same com-
munities in 2005, which were typically <30% (Supplementary
Table C). Some of this discrepancy is probably because the
10% value (and the previous estimates from these communities)
was based on geometric means, which are not strictly comparable
with the model-derived repopulation rates presented here (which
correspond to arithmetic means). Furthermore, the sampling
scheme employed in this study (and previously in the same com-
munities [19]) followed up only participants who were positive
for microfilariae at recruitment. This ensures that only people in-
fected withO. volvulus are repeatedly skin snipped, increasing the
efficiency of sampling when the prevalence of infection is low.
Unfortunately, this necessary protocol potentially introduces
sampling biases because the sensitivity of skin snipping declines
with decreasing infection intensity [31]. Hence, participants with
less intense infections are more likely to be erroneously deemed
uninfected and not followed up. This will probably upwardly bias
repopulation rates because more intensely infected people will
have more microfilariae after a period of repopulation than
those with less intense infections.
Notwithstanding these cautions, the 3 communities with the
highest repopulation rates over the 2 repopulation periods (Asu-
bende, Kyingakrom, New Longoro) have been previously impli-
cated as responding suboptimally to ivermectin [19, 20, 27]. A
mechanistic cause underlying these observations cannot be de-
termined from the statistical analysis presented here. However,
previous suggestions that faster rates of skin repopulation by
microfilariae might result from a sudden increase in new infec-
tions between treatment rounds—perhaps due to programmatic
deficiencies in coverage and compliance [32,33]—aredifficult to
reconcile with the generally high levels of therapeutic coverage
observed throughout (Figure 6D) and before (Supplementary
Figure A) the study. It is more likely that transmission has
been declining since the onset of biannual ivermectin treatment
in July 2010, as evidenced by the generally falling CMFL (Fig-
ure 3), although the resilience of community infection levels to
biannual distribution in Kyingakrom is noteworthy (Supple-
mentary Tables A and B).
Work is ongoing to evaluate the genotype of adult parasites
extracted from some of the participants of this study. Previous
analyses comparing allele frequencies among adult female
O. volvulus infecting people in multiply treated and ivermectin-
naive populations in Ghana and Cameroon identified selection of
P-glycoprotein and β-tubulin genes, both associated with resis-
tance to ivermectin in helminth infections of livestock [34, 35].
Moreover, a genetic analysis of the entire region of the β-tubulin
gene extracted from worms infecting people from Kyingakrom—
a consistently implicated suboptimally responding community—
has identified statistically significantly higher frequencies of 6
single-nucleotide polymorphisms [36]. How the phenotypic
response of individual worms relates to these genetic changes re-
mains incompletely understood. Worms collected from subopti-
mally responding communities have been associated with higher
fertility than worms from putatively normally responding com-
munities [36], possibly indicative of a faster resumption of fertil-
ity following exposure to ivermectin [28]. However, results
Figure 5. Six-month microfilarial repopulation rates in 10 Ghanaian communities
from the onset of a biannual ivermectin treatment strategy. Filled and open data
points represent, respectively, estimated mean microfilarial loads 6 months after
the first or second round of ivermectin treatment, expressed as a percentage of
the microfilarial load estimated just before the preceding round of ivermectin treat-
ment. These estimates are derived from Model 1B, Table 2, which adjusts for the
variable follow-up times among communities, permitting estimation of directly com-
parable standardized 6-month rates of repopulation. The 6-month microfilarial repop-
ulation rate from Baaya is not shown because only 1 participant was microfilaria
positive and followed up in this community (Table 1), leading to very large associated
estimates of uncertainty. Vertical lines indicate 95% confidence bounds, calculated
using robust sandwich estimators of coefficient standard errors (Supplementary
Methods). P values comparing the rate of repopulation with the reference village
of Takumdo: ***P < .001; **P < .01.
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elsewhere suggest that selection driven by exposure to ivermectin
is associated with a pleiotropic fitness cost of decreased fertility
[35], so perhaps putatively resistant worms can resume produc-
tion of microfilariae more rapidly than their susceptible counter-
parts, but ultimately have less reproductive potential.
Our conclusions on microfilarial repopulation rates are based
on average, community estimates, adjusted for individual (host)
characteristics such as age and sex. This is consistent with the in-
ferential basis of previous, more descriptive analyses of data from
some of the same communities studied here [19, 27]. Yet, partic-
ularly for these well-studied and relatively small communities,
many of the same individuals have probably repeatedly partici-
pated in the epidemiological studies undertaken over the last
15 years. Hence, future analyses should focus on estimating
drug responses at the individual level [37, 38]. It is more plausible
that certain individuals, rather than entire communities, are con-
sistently responding poorly to ivermectin (and influencing the
community-wide response). Poor individual responses to treat-
ment might be caused by host-related factors or, given the long
lifespan of adult O. volvulus, by drug-tolerant parasites.
The biannual ivermectin treatment strategy is markedly re-
ducing O. volvulus infection levels in Ghana. However, despite
Figure 6. Relative 6-month microfilarial repopulation rates in 10 Ghanaian communities over the first 2 rounds of a biannual ivermectin treatment strategy. Data points
represent the estimated relative (multiplicative) 6-month microfilarial repopulation in each community compared with Takumdo. Six-month repopulation rates are defined as
mean microfilarial loads 6 months after a round of ivermectin treatment, expressed as a percentage of the microfilarial load estimated just before the preceding treatment
round. Estimates are derived from Model 2, Table 2, which treats time since the preceding ivermectin treatment as a continuous covariate interacting with the indicator
covariate for community. The 6-month microfilarial repopulation rate from Baaya is not shown because only 1 participant was microfilaria positive (Table 1), leading to
very large associated estimates of uncertainty. A, Estimates are plotted side-by-side for the different communities. B, Estimates are plotted against the number of years
of ivermectin treatment preceding the biannual strategy. C, Estimates are plotted against community microfilarial load (CMFL) preceding the first biannual ivermectin treatment.
D, Estimates are plotted against the mean coverage of ivermectin distribution for the years 2010 and 2011, corresponding to the component of the study when the longitudinal
cohort of participants was followed up over 2 consecutive rounds of biannual treatment (see also Supplementary Figure A for disaggregated coverage data from 2005 to 2013).
Vertical lines are 95% confidence bounds, calculated using robust sandwich estimators of coefficient standard errors (Supplementary Methods). Solid horizontal lines in (C)
indicate 95% confidence bounds associated with the estimated CMFL, calculated using a numerical bootstrap resampling method (Supplementary Methods). *P < .05, com-
paring with the reference village of Takumdo.
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high and sustained therapeutic coverage, suboptimal responses
to ivermectin persist in previously implicated communities.
Whether this is caused by drug-tolerant or resistant parasites,
or by host-related factors, remains unclear. Analyses are yet to
be performed to test the hypothesis that community-level sub-
optimal responses are driven by a minority of consistently poor-
ly responding individuals (or their worms) and to identify
underlying mechanisms. The EPIONCHO and ONCHOSIM
mathematical transmission models are being used to assess
the feasibility of meeting the WHO elimination goals with an-
nual or biannual ivermectin treatment [29, 30, 38, 39], and in the
future they will be used to establish which settings may require
alternative or complementary strategies (such as test-and-treat
macrofilaricidal doxycycline therapy [40] and/or focal vector
control). Such modeling projections cover a wide range of
epidemiological and programmatic contexts, but should also ac-
commodate the possibility that ivermectin may not be as uni-
versally efficacious as hoped.
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